Pairawan, Seyed
Akcakanat, Argun
Kopetz, Scott
Tapia, Coya
Zheng, Xiaofeng
Chen, Huiqin
Ha, Min Jin
Rizvi, Yasmeen
Holla, Vijaykumar
Wang, Jing
Evans, Kurt W.
Zhao, Ming
Busaidy, Naifa
Fang, Bingliang
Roth, Jack A.
Dumbrava, Ecaterina Ileana
Meric-Bernstam, Funda
Funding for this research was provided by:
National Institutes of Health (CA009599, U54CA224065, 1UL1TR003167)
Article History
Received: 12 July 2021
Accepted: 14 December 2021
First Online: 24 January 2022
Competing interests
: S.P., A.A., X.Z., H.C., M.J.H., Y.R., V.H., J.W., K.W.E., M.Z., N.B., B.F., and E.I.D. declare no competing interests. C.T. is an employee of Epizyme Inc. and performed contract work for Armo Bioscience. S.K. reports receiving commercial research grants from Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, and Lilly. He also served as a consultant or advisor for Roche, Genentech, EMD Serono, Merck, Karyopharm Therapeutics, Amal Therapeutics, Navire Pharma, Symphogen, Holy Stone, Biocartis, Amgen, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, EMD Serono, Redx Pharma, Ipsen, Daiichi Sankyo, and Natera. He has stock and other ownership interests in MolecularMatch and Navire. J.A.R. reports receiving a commercial research grant from The University of Texas MD Anderson Cancer Center. He has a sponsored research agreement from Genprex Inc, has ownership interest (including stock, patents, etc.) in Genprex Inc., and is a consultant/advisory board member for Genprex Inc. F.M.-B. reports receiving commercial research grants from Aileron Therapeutics Inc.; AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Millennium Pharmaceuticals Inc., Novartis, Puma Biotechnology Inc., and Taiho Pharmaceutical Co. She also served as a consultant for Aduro BioTech Inc., DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech Inc., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor, and Zymeworks. Additionally, she serves on the advisory committee for Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals and Zentalis. C.T., S.K., J.A.R., and F.M.-B. declare that the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.